Clinical Investigation of Safety and Efficacy of the Emerald IPL Device for Hair Reduction for the Extension of Its Intended Use to Face and to Skin Type V Population
Clinical Investigation of Safety and Efficacy of the Emerald IPL Device for Hair Reduction for the Extension of Its Intended Use to Face and to Skin Type V Population
Prospective, multi-center, single-arm, single blinded (Philips hair counter) study in healthy women of skin types I up to and including V.
Safety and efficacy of hair removal with the Emerald IPL-device will be investigated for treatment in face of subjects with ST I - IV and for treatment in face, axilla, bikini area, and legs of subjects with ST V.
In-clinic, the study subjects will undergo twelve IPL-treatments bilaterally at the qualified areas (face and / or axilla, bikini line, and legs) with the Emerald IPL device applied by a device operator.
Hair re-growth in each area will be evaluated separately and across all skin types.
After the 4 bi-weekly treatments, one follow-up visit will be organized two weeks after the 4th treatment. After the completion of the full treatment cycle (12 treatments), subjects will be followed for 1 and 3 months (short-term follow-up) and for 6, 9 and 12 months (long-term follow up).
Hair grows in cyclic phases: anagen, catagen and telogen. These phases impact on how the process of light-based hair removal works. The hair grows during the anagen phase, which has the longest duration in the hair growth cycle. Hair growth ends with the transition from anagen into the catagen phase, a short transition phase to prepare for the resting phase, the telogen, which ends with shedding of the hair and the start of the hair growth cycle. During telogen phase, the hair follicle remains inactive. Each hair follicle is independent and goes through the growth cycle at different times. As presented in table 5 [11], the duration of the growth cycle of the upper lip, axilla and bikini line are different from that of the legs. In general, the telogen and anagen phase's durations of the cycle are longest for the legs (i.e., 24 and 16 weeks, respectively) and the shortest for upper lip (i.e. 6 weeks for both phases). Therefore, hair response to the IPL treatment will be evaluated by body area.
The efficacy of permanent hair reduction will be measured following the definition of permanent hair reduction according to the FDA as follows: "Permanent hair reduction is defined as the long-term, stable reduction in the number of hairs re-growing after a treatment regime, which may include several sessions. The number of hairs re-growing must be stable over time greater than the duration of the complete growth cycle of hair follicles, which varies from four to twelve months according to body location. Permanent hair reduction does not necessarily imply the elimination of all hairs in the treatment area."
In an attempt to promote permanent hair reduction, the aim is to expose all hairs at least once to an IPL flash and therefore treatment will cover the full duration of a hair growth cycle). The longest relevant full hair growth cycle is on the legs (40 weeks, excluding approximately 2 weeks for the catagen phase). Therefore, a treatment duration of 10 months (approximately 38weeks) has been selected: a full IPL treatment cycle consists of 4 initial treatments, once every 2 weeks, followed by 8 maintenance (monthly) treatments, once every 4 weeks. The hair growth cycle on face (upper lip) is the shortest (12 weeks, 6 weeks in anagen, 6 weeks in telogen phases). The initial treatments in 2 weeks interval are expected to be most beneficial for face treatment.
For this study, there are two cohorts for enrollment:
The visits are as follows:
Screening Visit: The volunteers are screened to identify subjects who meet all of the inclusion and none of the exclusion criteria. Device settings are selected based on skin tone and comfort evaluation..
Visits 1-4 (TX1-TX4): Four treatments and the collection of safety and efficacy data are scheduled to occur every 2 weeks/ 14 days; Visits 5 (Initial Treatment 2wk Follow-up): Safety and efficacy data are collected 2 weeks/ 14 days after 4th treatment to demonstrate hair removal performance 8 weeks after baseline.
Inclusion Criteria:
Be willing to provide informed consent
Are healthy female subjects, in age of 18-65 years
Have natural body hair color that is dark blonde, brown or black in the designated treatment areas
3.1. Subjects of ST I-IV - Face group:
3.1.1 Have Fitzpatrick Skin Type I, II, III, or IV
3.1.2 Measure melanin value ≤ 375 in the qualifying treatment areas bilateral on upper lip (face)
3.1.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection
3.2. Subjects of ST V - All body area group:
3.2.1. Have Fitzpatrick Skin Type V
3.2.2. Measure melanin value ≤ 553 in the qualifying treatment areas bilateral on upper lip (face), axilla, bikini line, and leg
3.2.3. Have a minimum of 10 hairs in the 1x2cm2 qualifying treatment areas bilateral on upper lip (face), by visual inspection
3.2.4.Have a minimum of 24 hairs in each of the 2x4cm2 qualifying treatment areas bilateral on axilla, bikini line, and leg, by visual inspection
Be either post-menopausal or surgically sterilized, or using a medically acceptable form of birth control (e.g., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide or abstinence, etc.).
Be willing to participate in all study visits
Be willing to refrain from deliberate exposure to strong sun, products or procedures that would cause the skin to become darker in the designated treatment areas during the treatment phase
Be willing to refrain from the use of hair growth inhibitors/accelerators during the course of the study
Be willing to refrain from waxing, depilating or epilating of the axilla, bikini line, leg, and face
Be willing to refrain from using aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) within 5 days prior to and 5 days after treatment(s) -
Exclusion Criteria:
Have natural body hair color that is white, light blond, or red in the designated treatment areas
1.1. Subjects of ST I to IV - Face group:
1.1.1. Have Fitzpatrick Skin Type V or VI
1.1.2. Measure melanin value higher than 375 in the qualifying treatment areas bilateral on upper lip
1.1.3. Have fewer than 2 qualifying treatment areas on bilateral on upper lip (face)
1.2. Subjects of ST V - All body area group:
1.2.1. Have Fitzpatrick Skin Type I, II, III, IV, or VI
1.2.2. Measure melanin value higher than 553 in any of the qualifying treatment areas bilateral on the body
1.2.3. Have fewer than 8 qualifying treatment areas bilateral: 2 in face, 2 in axilla, 2 on bikini line, and 2 on legs
Have a malignant or pre-malignant pigment in the area to be treated
Have scarring or infection of the area to be treated
Have a known history of photosensitivity or use of medication known to induce photosensitivity
Are currently pregnant or lactating or planning be become pregnant in the period of the study, per subject report
Are currently on a daily dose of aspirin or NSAIDs (e.g. acetaminophen, ibuprofen, etc.) or have taken aspirin and/or NSAIDs within 5 days prior to treatment that would reduce or increase the sensation of pain
Are not willing to abstain from the use of products or light exposure that would induce tanning in the treatment areas during the IPL treatment period (first 10 months)
Have a history of immunosuppressive disease (including HIV infection or AIDS)
Are on a anticoagulative medication or thromboembolic condition
Have taken any form of isotretinoin (such as Accutane or Roaccutane etc.) in the last six months
Have an active implantable device such as a pacemaker, neurostimulator or internal defibrillator
Have used waxing or other methods of root hair removal, or photo-epilation in the areas to be treated within 6 months prior to treatment
Have been exposed to strong sunlight or an artificial tanning machine in the area to be treated within 4 weeks of enrolment
Have a tattoo(s), warts, moles, benign skin lesions, dark pigmented areas, permanent make-up etc. in the areas to be treated.
Have eczema, psoriasis, lesions, open wounds or any skin affliction in the areas to be treated
Have a history of keloid scar formation
Have a history of herpes outbreaks in the areas to be treated
Have a history of photosensitive epilepsy
Have a condition related to hormonal changes like polycystic ovarian syndrome (PCOS) or taking drugs leading to hormonal changes resulting in excessive hair growth like hirsutism or idiopathic hirsutism
Have diabetes, or metabolic disease that affects hair growth
Taking immunosuppressive medication(s)
Have a disease related to photosensitivity, such as polymorphic light eruption (PMLE), solar urticaria, porphyria etc.
Have a history of skin cancer, including past basal cell carcinoma and/or squamous cell carcinoma in the areas to be treated
Have a history of any radiation therapy in any of the areas to be treated
Have history of radiation therapy in non-treatment areas within 5 years
Have a history of chemotherapy
Have used hair growth inhibitors and/or accelerators within 6 months preceding enrolment
Have had laser or electrolysis treatment for the removal of hair in the areas to be treated within the last year
Have natural body hair colors of white, grey, light to mid-blond, or red in the areas to be treated
Have bleaching of their body hair in the areas to be treated 6 months prior to study enrolment
Have shaved the areas to be treated within 7 days prior to study enrolment
Participating in other clinical studies prior to, or concurrently with this study, that could be deemed to interfere with full and complete participation in this study - as determined by the site investigator.